COVID-19の発生は、世界中でCOVID-19の評価のために血液学的パラメーターへの関心が高まっているため、血液学市場に大きな影響を与えると予想されています。また、多くの病院がCOVID-19患者の検査と監視のために血液学分析装置などの機器を使用し始めています。2020年に発表された『国際検査血液学ジャーナル』に掲載された研究記事によると、臨床血液学検査室は、リンパ球減少症、好中球増加症、白血球増加症、血小板減少症など、SARS-CoV-2ウイルスに感染した患者に共通するいくつかの有用な予後マーカーを提供する重要な役割を果たしています。2021年のアメリカ血液学会の報告によると、COVID-19および鎌状赤血球症（SCD）の患者は、SCDのない黒人と比較して入院、肺炎の発症、痛みのリスクが高いままでした。SCDの患者は他の感染症を発症するリスクが高いため、健康の監視が重要であり、これは市場にかなりの影響を与えました。したがって、COVID-19に感染した患者における血液学的検査の重要性の高まりは、さまざまな最終利用者における血液学製品および試薬の需要を急増させると予想され、それによって調査対象の市場の成長に大きな影響を与えるでしょう。

さらに、2020年10月にCellaVision ABは、臨床検査室での体外診断に使用される自動細胞定位装置CellaVision DC-1の米国食品医薬品監督局（FDA）510(k)プレマーケット承認を取得しました。また、白血球の分化計数、赤血球形態の特性評価、および血小板推定のために使用されるCellaVision DC-1 PPAも承認されました。さらに、2020年11月にSysmex Americaは、米国およびカナダの低ボリューム血液学検査室向けにFDAからクリアランスを受けたClearVision DC-1を配布すると発表しました。加えて、2022年1月にSight Diagnosticsは、ポイントオブケア環境向けにSight OLO分析装置のカナダ保健省の承認を受けました。Sightは、流通パートナーであるInter Medicoを通じて、カナダ全土の救急部門、病院、その他の分散型環境に5部位の差分血液検査を提供し、市場を推進します。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場力学

  • 4.1 市場概要

  • 4.2 市場の促進要因

    • 4.2.1 血液疾患などの疾病の増加

    • 4.2.2 ヘマトロジーの急速な技術的進歩

    • 4.2.3 ハイスループット型ヘマトロジーアナライザーの登場

  • 4.3 市場の抑制要因

    • 4.3.1 高価な楽器

    • 4.3.2 新興国におけるヘマトロジーアナライザーの普及率の低さ

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模、百万米ドル）

  • 5.1 製品別

    • 5.1.1 ヘマトロジーアナライザー

    • 5.1.2 フローサイトメーター

    • 5.1.3 凝固分析装置

    • 5.1.4 スライドステイナー

    • 5.1.5 遠心分離機

    • 5.1.6 ヘモグロビン計

    • 5.1.7 その他の製品

  • 5.2 試薬による

    • 5.2.1 凝固試薬

    • 5.2.2 フローサイトメトリー用試薬

    • 5.2.3 免疫血液学関連試薬

    • 5.2.4 その他試薬

  • 5.3 用途別

    • 5.3.1 薬物検査

    • 5.3.2 自己免疫疾患

    • 5.3.3 がん

    • 5.3.4 糖尿病

    • 5.3.5 感染症

    • 5.3.6 その他の用途

  • 5.4 エンドユーザー別

    • 5.4.1 病院

    • 5.4.2 臨床試験機関

    • 5.4.3 患者さんの自己診断

    • 5.4.4 その他のエンドユーザー

  • 5.5 地域別

    • 5.5.1 北米

      • 5.5.1.1 米国
      • 5.5.1.2 カナダ
      • 5.5.1.3 メキシコ

    • 5.5.2 ヨーロッパ

      • 5.5.2.1 ドイツ
      • 5.5.2.2 英国
      • 5.5.2.3 フランス
      • 5.5.2.4 イタリア
      • 5.5.2.5 スペイン
      • 5.5.2.6 その他ヨーロッパ

    • 5.5.3 アジア太平洋

      • 5.5.3.1 中国
      • 5.5.3.2 日本
      • 5.5.3.3 インド
      • 5.5.3.4 オーストラリア
      • 5.5.3.5 韓国
      • 5.5.3.6 その他アジア太平洋

    • 5.5.4 中東・アフリカ

      • 5.5.4.1 GCC地域
      • 5.5.4.2 南アフリカ
      • 5.5.4.3 その他中東・アフリカ

    • 5.5.5 南米

      • 5.5.5.1 ブラジル
      • 5.5.5.2 アルゼンチン
      • 5.5.5.3 その他南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 Abbott Laboratories

    • 6.1.2 Agilent Technologies Inc

    • 6.1.3 Bio-Rad Laboratories Inc

    • 6.1.4 Danaher Corporation

    • 6.1.5 Diatron MI PLC (Stratec Biomedical Systems)

    • 6.1.6 F.Hoffmann-La Roche AG

    • 6.1.7 Novo Nordisk AS

    • 6.1.8 Fluidigm Corporation

    • 6.1.9 Drew Scientific Group

    • 6.1.10 PerkinElmer Inc

    • 6.1.11 Thermo Fisher Scientific Inc

    • 6.1.12 Ortho Clinical Diagnostics

    • 6.1.13 Siemens Healthineers

    • 6.1.14 Sysmex Corporation

    • 6.1.15 Shenzhen Mindray Bio-Medical Electronics Co. Ltd

• 7 市場機会と今後の動向

The hematology market is expected to record a CAGR of 5.2% over the forecast period (2022-2027).

The COVID-19 outbreak is expected to have a significant impact on the hematology market as there is an increasing focus on hematology parameters for the assessment of COVID-19 around the world, and many hospitals have started using instruments such as hematology analyzers to test and monitor COVID-19 patients. According to the research article published in the International Journal of Laboratory Hematology, 2020, a clinical hematology laboratory has a critical role in providing several useful prognostic markers such as lymphopenia, neutrophilia, leukocytosis, and thrombocytopenia, which are common findings in patients infected with SARS-CoV-2 virus. According to the report published in the American Society of Hematology 2021, Patients with COVID-19 and sickle cell disease (SCD) remained at a higher risk of hospitalization, pneumonia development, and pain when compared to Black people without SCD. As the people with SCD were at higher risk of developing other infections, it was important to monitor their health which has considerably impacted the market. Thus, the growing importance of hematological testing in COVID-19 infected patients is expected to surge the demand for hematology products and reagents across various end users, thereby significantly impacting the studied market’s growth during the pandemic era.

The growth of the hematology market is attributed to the increasing incidences of blood disorders and other diseases, rapid technological advances in hematology, and the emergence of high throughput hematology analyzers. The increasing prevalence of chronic blood disorders is one of the major factors driving the market, as it is expected to drive the demand for hematology analyzers. Coagulation analyzers can accurately detect the clotting endpoint in various blood disorders, such as hemophilia. People can be affected by various types of blood conditions and blood cancers. Common chronic blood disorders include anemia, bleeding disorders such as hemophilia and blood clots, and blood cancers such as leukemia, lymphoma, and myeloma. As per the May 2022 update by the Center for Disease Control and Prevention, sickle cell disease (SCD) affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African American births. Early diagnosis and treatment are the best ways to protect the life of a patient with blood cell disorder.

Additionally, the technological advancements and product launches by key players have been driving the market growth. For instance, in June 2022, Thermo Fisher Scientific Inc. introduced the new EliA RNA Pol III and EliA Rib-P blood tests for aiding in the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematosus (SLE), thus further expanding its comprehensive menu of automated connective tissue disease tests. According to an article “RURAL Study to Use HemoScreen POC Hematology Analyzer” published in February 2021, the Risk Underlying Rural Areas Longitudinal Study (RURAL) was conducted to understand the health concerns facing people in rural communities who don’t have the same healthcare access as urban parts. This study plans to deploy technology advanced HemoScreen hematology analyzers in the Mobile Examination Unit lab to test the performance characteristics of the HemoScreen in those setting. Thus, the research proving the efficacy of technologically advanced product will boost the ongoing innovation in the market, thus fueling the market growth. Thus, owing to the abovementioned factors, the hematology market is expected to witness significant growth over the forecast period. However, the high cost of the instruments and the low adoption of hematology analyzers in the emerging economies are anticipated to hamper the market growth in the coming years.

Key Market Trends

The Hematology Analyzers Segment is Expected to Register Significant Growth Over the Forecast Period

Hematology analyzers are instruments used to run tests based on blood samples. They are used to perform tests such as complete blood count, including red blood cell, white blood cell, platelet, and hemoglobin count, along with characterizing the blood cells to diagnose a disease condition. The growing burden of blood-related disorders, which drives the demand for hematology tests, and advancements in technology for the development of hematology analyzers with advanced features are the major drivers for the growth of the studied segment.

For instance, in May 2020, Beckman Coulter, a subsidiary of Danaher Corporation, launched its DxH 690T hematology analyzer in the United States, which enables mid-volume laboratories to streamline workflow and maximize uptime. Additionally, in July 2022, HORIBA Medical launched new products in its Yumizen H500 & H550 hematology product family, the compact benchtop hematology analyzers with enhanced performance, new features, and increased benefits. These products have been designed to deliver a rapid and comprehensive hematology report with a throughput of 60 tests/hour, 40 tubes autonomy with continuous loading, urgent manual mode; and for running samples through multi-analysis modes and sampling.

Moreover, rising research and development activities proving the efficacies of hematology analyzers are expected to positively contribute to the market growth. For instance, according to a study titled 'Establishment of improved review criteria for hematology analyzers in cancer hospitals' published in February 2021, automated hematologic analyzers are widely used in medical laboratories. This condition in the hospitals will boost the studied hematology analyzers segment of the cell surface markers detection market.

Also, strategic alliances such as acquisitions, partnerships, and collaborations by key players are driving the segment growth. For instance, in September 2020, Cyient entered a manufacturing partnership with Agappe to manufacture certain key components of Mispa Count X at its ISO 13485-certified, state-of-the-art manufacturing facilities in India. The Mispa Count X is an indigenously designed and developed three-part hematology analyzer by Agappe.

Thus, due to the above-mentioned factors, the studied segment is expected to contribute positively to the market growth during the study period.

The North American Region Holds the Largest Market Share, and it is Expected to Follow the Same Trend over the Forecast Period

The United States within North America is expected to witness significant growth in the hematology market in the coming years due to factors such as the increasing incidence of blood disorders, technological advancements, and increasing product launches in the region. As per an October 2021 update by the National Cancer Institute, acute myeloid leukemia is the most common type of acute leukemia in adults. In addition, as per the 2021 statistics by the Leukemia & Lymphoma Society, an estimated 397,501 people are living with or in remission from leukemia in the United States. The growing burden of blood disorders such as leukemia is expected to surge the demand for hematology instruments and reagents, thus driving the market growth in the region. According to the study “Decreased Iron Intake Parallels Rising Iron Deficiency Anemia and Related Mortality Rates in the United States Population” published in July 2021, the prevalence of estimated anemia in the United States ranged from 10.5% to 106% depending on the age and sex. Thus, the high prevalence of the disease in the country demands a high number of blood tests, thus driving the market.

Additionally, in October 2020, CellaVision AB received the United States Food and Drug Administration’s 510(k) premarket approval for its CellaVision DC-1, which is an automated cell-locating device intended to be used in in vitro diagnostics in clinical laboratories, and CellaVision DC-1 PPA, which is intended for the differential count of white blood cells, characterization of red blood cell morphology, and platelet estimation. Further, in November 2020, Sysmex America announced that it would distribute the FDA-cleared ClearVision DC-1 for low-volume hematology laboratories in the United States and Canada. Additionally, in January 2022, Sight Diagnostics received Health Canada approval to provide Sight OLO analyzers for point-of-care settings. Through its distribution partner Inter Medico, Sight will bring the 5-part differential blood testing to emergency departments, hospitals, and other decentralized settings across Canada, thereby driving the market.

Thus, owing to the abovementioned factors, the market is expected to witness significant growth in the forecast period in the North American region.

Competitive Landscape

The hematology market is fragmented and moderately competitive. Some key industry players include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens Healthineers, F. Hoffmann-La Roche Ltd etc. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, partnerships, and investments in research and development activities, which help them strengthen their market positions globally.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Increasing Incidences of Blood Disorders and Other Diseases

    • 4.2.2 Rapid Technological Advances in Hematology

    • 4.2.3 Emergence of High Throughput Hematology Analyzers

  • 4.3 Market Restraints

    • 4.3.1 High Cost of Instruments

    • 4.3.2 Low Adoption of Hematology Analyzers in Emerging Economies

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product

    • 5.1.1 Hematology Analyzers

    • 5.1.2 Flow Cytometers

    • 5.1.3 Coagulation Analyzers

    • 5.1.4 Slide Stainers

    • 5.1.5 Centrifuges

    • 5.1.6 Hemoglobinometers

    • 5.1.7 Other Products

  • 5.2 By Reagent

    • 5.2.1 Coagulation Reagents

    • 5.2.2 Flow Cytometery Reagents

    • 5.2.3 Immuno-hematology Reagents

    • 5.2.4 Other Reagents

  • 5.3 By Application

    • 5.3.1 Drug Testing

    • 5.3.2 Auto-immune Diseases

    • 5.3.3 Cancer

    • 5.3.4 Diabetes Mellitus

    • 5.3.5 Infectious Diseases

    • 5.3.6 Other Applications

  • 5.4 By End User

    • 5.4.1 Hospitals

    • 5.4.2 Clinical Testing Institutes

    • 5.4.3 Patient Self-testing

    • 5.4.4 Other End Users

  • 5.5 Geography

    • 5.5.1 North America

      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico

    • 5.5.2 Europe

      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe

    • 5.5.3 Asia-Pacific

      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific

    • 5.5.4 Middle East and Africa

      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa

    • 5.5.5 South America

      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Abbott Laboratories

    • 6.1.2 Agilent Technologies Inc

    • 6.1.3 Bio-Rad Laboratories Inc

    • 6.1.4 Danaher Corporation

    • 6.1.5 Diatron MI PLC (Stratec Biomedical Systems)

    • 6.1.6 F.Hoffmann-La Roche AG

    • 6.1.7 Novo Nordisk AS

    • 6.1.8 Fluidigm Corporation

    • 6.1.9 Drew Scientific Group

    • 6.1.10 PerkinElmer Inc

    • 6.1.11 Thermo Fisher Scientific Inc

    • 6.1.12 Ortho Clinical Diagnostics

    • 6.1.13 Siemens Healthineers

    • 6.1.14 Sysmex Corporation

    • 6.1.15 Shenzhen Mindray Bio-Medical Electronics Co. Ltd

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS